Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing.
LamPORE
SARS-CoV-2
diagnosis
nanopore sequencing
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
19 05 2021
19 05 2021
Historique:
received:
30
12
2020
accepted:
23
03
2021
pubmed:
31
3
2021
medline:
24
6
2021
entrez:
30
3
2021
Statut:
epublish
Résumé
LamPORE is a novel diagnostic platform for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA combining loop-mediated isothermal amplification with nanopore sequencing, which could potentially be used to analyze thousands of samples per day on a single instrument. We evaluated the performance of LamPORE against reverse transcriptase PCR (RT-PCR) using RNA extracted from spiked respiratory samples and stored nose and throat swabs collected at two UK hospitals. The limit of detection of LamPORE was 10 genome copies/μl of extracted RNA, which is above the limit achievable by RT-PCR, but was not associated with a significant reduction of sensitivity in clinical samples. Positive clinical specimens came mostly from patients with acute symptomatic infection, and among them, LamPORE had a diagnostic sensitivity of 99.1% (226/228; 95% confidence interval [CI], 96.9% to 99.9%). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (278/279; 98.0% to 100.0%). Overall, 1.4% (7/514; 0.5% to 2.9%) of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8% (478/494; 94.8% to 98.1%). LamPORE has a similar performance as RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients and offers a promising approach to high-throughput testing.
Identifiants
pubmed: 33782112
pii: JCM.03271-20
doi: 10.1128/JCM.03271-20
pmc: PMC8315953
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Peto et al.
Références
J Biochem Biophys Methods. 2007 Apr 10;70(3):499-501
pubmed: 17011631
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
J Infect. 2021 Jan;82(1):159-198
pubmed: 32474037
J Infect. 2021 Jan;82(1):117-125
pubmed: 33271166
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
J Clin Virol. 2020 Nov;132:104616
pubmed: 32891938
ACS Cent Sci. 2021 Feb 24;7(2):307-317
pubmed: 33649735
R Soc Open Sci. 2020 Jun 24;7(6):200915
pubmed: 32742705
Anal Chem. 2007 Aug 1;79(15):5608-13
pubmed: 17579496
Biotechniques. 2020 Sep;69(3):178-185
pubmed: 32635743
Clin Infect Dis. 2020 Dec 03;:
pubmed: 33270107
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32719001
Infect Dis Ther. 2020 Sep;9(3):573-586
pubmed: 32725536
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387